Navigation Links
Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary
Date:6/24/2008

d mean failing to realize potentially significant profits. We believe that the cost of boosting Taro's short-term cash flows in this manner is too high. Shareholder value is best optimized by cultivating Taro Ireland as a source of future revenues.

We have set out the facts as they appear to us, and are confident that when other shareholders are provided with full disclosure, they will agree entirely with us as to the long-term potential of Taro Ireland and support our objections to the proposed sale. If you feel that we have gotten the wrong impression, we are sure that you will not hesitate to provide Taro's shareholders with full disclosure as to: (i) the total investment made in Taro Ireland to date, including capitalized losses; (ii) the present asset base of Taro Ireland; (iii) Taro Ireland's financials for the last five years (including sales, expenditure and profits); and (iv) Taro Ireland's products which have been, or are in the process of being, approved by the Irish and other authorities.

2. Unfavorable Terms of Proposed Sale. In addition to the questionable rationale for the proposed sale, we have serious misgivings about the patently unfavorable terms of such sale, which include:

(i) Significant undervaluation of the Irish operations. You previously sought our permission under the Merger Agreement to sell Taro Ireland for less than the value of the real estate on which the facilities stand. Such a price would be lower than Taro Ireland's existing asset value, even without taking into account the probable future growth described above; and

(ii) A form of consideration which puts the risk on Taro. We understand that the proposed consideration includes earn-out payments based on future profits, which are contingent on the third party buyer's performance, and are not within Taro's control. Further, such amounts, if payable, will only be received at some future time. Your acceptance of such contingent payments contradicts your os
'/>"/>

SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
2. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
3. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
4. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
5. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
6. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
7. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
8. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
9. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
10. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
11. GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... advanced cell culture products, announces the availability of BI’s line of human mesenchymal ... Industries, these stem cell differentiation media offer a complete system for multipotency evaluation ...
(Date:7/28/2015)... ... ... new Xsample 530 sample changer for vials can be used with Anton Paar ... less than 12,000 mPas (internal air) up to 36,000 (external air) – and can process ... about Xsample 530 is its removable magazine, which is easily lifted off its hub and ...
(Date:7/28/2015)... July 21, 2015 ... the addition of the "Analysis of the ... their offering. Globally, flow cytometry remains ... cell proliferation, cancer, and stem cells. But the ... primarily because of demand from underdeveloped nations to ...
(Date:7/28/2015)... , July 28, 2015  Kerastem Technologies announce that ... the U.S. FDA Center For Biologics Evaluation and Research ... conduct a clinical trial investigating the safety and feasibility ... and early male pattern baldness (androgenic alopecia). ... follows initial clinical work in Europe ...
Breaking Biology Technology:Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3New Moves in Automatic Sample Handling: Introducing Xsample 530 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2
... , ... Director, Clinical Services, will lead a panel of life sciences executives on the topic ... center around risk/reward approaches and technology collaboration among clinical trial sponsors and service providers ... ...
... COPENHAGEN, July 14 When world political leaders are ... Climate Change Conference in December 2009, environmentally friendly fuel ... Biofuels, a co-operation between Danisco,s biotech division Genencor, Inbicon, ... generation bioethanol for 40 of the cars that the ...
... ... ... July 14, 2009 -- Quantros, a leading provider of safety and quality software and ... Hospital and USC Kenneth Norris, Jr. Cancer Hospital at the University of Southern California. ...
Cached Biology Technology:ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 2ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 3Politicians to Drive on Straw-Based Bioethanol at the Climate Change Conference 2Politicians to Drive on Straw-Based Bioethanol at the Climate Change Conference 3USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk 2USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk 3
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/7/2015)... June 30, 2015 ... the addition of the "Capacitive Fingerprint Sensors ... To this date, fingerprint sensing technology is ... fingerprint sensors are well developed. This patent landscape ... The domain of capacitive fingerprint sensors ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... researchers have devised a way to use a brief burst ... gold launch pad. The technique could someday be used to ... implanted in the body. The method also may be useful ... small quantities of a material. , The technique was described ...
... the Neanderthal genome, scientists suggest an early human-Neanderthal split. ... authors, but do not share much else after evolving ... issue of Science, also finds no evidence of genetic ... to explain the evolutionary relationship between Homo sapiens and ...
... DNA may not hold the key to your origins ... access journal BMC Biology reveals that fewer than 10% ... matched to mitochondrial DNA from one single African ethnic ... use of mitochondrial DNA to trace maternal ancestries, and ...
Cached Biology News:Electric jolt triggers release of biomolecules, nanoparticles 2Genetic study of Neanderthal DNA reveals early split between humans and Neanderthals 2Genetic study of Neanderthal DNA reveals early split between humans and Neanderthals 3
Anti-Protein Kinase-A (PKA) Regulatory subunit IIB; rabbit host...
... This protein is a member of the ... Members of the PAX family typically contain ... homeodomain. These proteins play critical roles during ... 3 are associated with Waardenburg syndrome, craniofacial-deafness-hand ...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
... in collaboration with Pall Life Sciences to ... a variety of membrane chemistries. The Automation ... the Caliper TPWII, MultiDose, Prelude, and Benchmate ... Automation Certified Syringe Filters are available at ...
Biology Products: